State of the Scan — October 2026

The research base is quietly rebalancing — away from single-marker cancer detection and toward integrated, systems-level views of aging, metabolism, and rare disease.

The big picture

Six months of scanning show a field in the middle of a structural shift rather than a single breakthrough moment. The sharpest movement isn't in any one headline therapy — it's in how researchers are framing disease itself. Cardiovascular, kidney, and metabolic conditions are converging into one continuum rather than three specialties; aging is being studied as a biological process with shared drivers (senescence, inflammation, frailty) rather than a backdrop to disease; and rare disease research is benefiting from the same infrastructure and AI tooling that used to be reserved for common cancers.

At the same time, some of the areas that dominated headlines earlier this year — early cancer detection via single biomarkers, novel oncology therapeutics narrowly defined, and genomics-first precision oncology — are cooling in relative volume even as the underlying technologies (liquid biopsy, ctDNA, immune profiling) mature and consolidate into fewer, more integrated platforms. This isn't retreat; it's the literature catching up to translate early discovery into validated, combinable tools.

What's heating up

• Rare diseases (+38%) — Momentum here is coming from infrastructure, not just new conditions. Multi-omic data consortia (e.g., GREGoR-style efforts) paired with single-cell and AI-driven mechanistic discovery are making rare disease diagnosis more systematic and less dependent on individual case reports.
• Aging & longevity (+29%) — Senescence and the senescence-associated secretory phenotype (SASP) are emerging as a unifying biological hub, linking mitochondrial stress, chronic inflammation, and immune remodeling across neurodegeneration and cancer alike.
• CBC diagnostics & ML in hematology (+11%) — Routine complete blood count parameters — neutrophil-to-lymphocyte ratio, platelet counts, composite indices like the Systemic Immune-Inflammation Index — are being re-purposed via machine learning into low-cost risk-stratification tools.
• Cardiovascular-metabolic (+11%) — The CKM (cardiovascular-kidney-metabolic) framing is consolidating type 2 diabetes, CKD, obesity, MASH, and hypertension into one treatment continuum, driving interest in therapeutics that act across multiple arms of that axis.
• Liquid biopsy and ctDNA topics (Plasma +500%, Circulating Tumor Cells +400%, Cancer Immunotherapy +250%) — Circulating tumor DNA and multi-omic circulating biomarkers (methylation signatures, circRNA, miRNA, exosomes, gasdermin fragments) are consolidating into standardized surveillance platforms that are displacing older methods like cystoscopy and routine imaging follow-up.

Cooling / quieter

• Early cancer detection (-23%) and multicancer early detection tests (-100% on this topic specifically) — Interest in single-test, pan-cancer screening approaches is fading as the field shifts toward combining cell-free DNA, protein, and cellular markers rather than betting on one assay.
• Precision oncology & genomics (-14%) and hematologic malignancies (-11%) — Genomic benchmarking and single-biomarker stratification (e.g., WT1, neutrophil-to-lymphocyte ratio as a standalone marker) are giving way to combination regimens and multi-marker models — the plumbing is being standardized rather than reinvented.
• Novel therapeutics narrowly defined (-17%), alongside cooling of "personalized treatment" as a standalone topic — suggesting coverage is folding single-drug narratives into broader combination and resistance-management stories instead.

Themes to watch

Cardiometabolic-Renal Convergence. The clearest macro-shift this year is the treatment of diabetes, chronic kidney disease, obesity, MASH, and hypertension as one interconnected syndrome — CKM — rather than separate referral pathways. Expect continued interest in therapeutics designed to act across this spectrum rather than targeting a single organ system, and in composite risk scores (like those capturing dynapenic abdominal obesity) that try to capture the interplay of adiposity, insulin resistance, sarcopenia, and inflammation in one number.

Senescence-Immune Crosstalk in Aging and Cancer. Cellular senescence and SASP are becoming the connective tissue between aging biology and oncology. In neurodegeneration, this shows up as a "blood-brain barrier senescence unit" — microglia, astrocytes, and pericytes behaving as a coordinated inflammatory front in Alzheimer's disease. In cancer, the same mitochondrial-stress-to-inflammation pathway is being explored as both a vulnerability and a resistance mechanism. This cross-disease framing is likely to keep gaining ground as a shared explanatory model.

Liquid Biopsy and ctDNA as the New Surveillance Backbone. Circulating tumor DNA, cell-free methylation signatures, circulating tumor cells, exosomes, and even cleaved protein fragments like gasdermins are converging into unified liquid biopsy platforms. The rising topics — Plasma, Circulating Tumor Cells, Colonoscopy, Esophageal and Cervical Cancer Screening — suggest this is moving from proof-of-concept biomarker papers toward validation against established procedures, a sign the technology is approaching clinical decision-making rather than just discovery.

Precision Cellular Immunotherapy and Resistance. CD19/CD20/LILRB4-directed cellular and bispecific therapies for B-cell and myeloid malignancies are facing their next hurdle: target escape and therapeutic resistance (+300% as a topic). The field's attention is turning from whether these therapies work to why they stop working and how to sequence or combine them — alongside parallel epigenetic work in myelodysplastic syndrome and AML aimed at refining regimens beyond blunt cytotoxic approaches.

The through-line

Across nearly every cluster, the same pattern repeats: single-marker, single-target approaches are consolidating into combination, multi-omic, and systems-level frameworks — whether that's CKM syndrome replacing siloed organ care, senescence replacing isolated aging theories, or multi-analyte liquid biopsies replacing one-shot cancer screens. The science isn't slowing down; it's integrating.

Not medical advice.